普罗布考片联合阿托伐他汀钙片与单用阿托伐他汀钙片治疗大动脉粥样硬化型脑梗死临床疗效的对比研究
发布时间：2018-08-03 08:55
【摘要】：目的比较普罗布考片联合阿托伐他汀钙片与单用阿托伐他汀钙片治疗大动脉粥样硬化型脑梗死患者的临床疗效。方法选取2012年1月—2015年5月威海市文登中心医院神经内科收治的大动脉粥样硬化型脑梗死患者110例,随机分为对照组与观察组,每组55例。在常规治疗基础上,对照组患者予以阿托伐他汀钙片治疗,观察组患者在对照组基础上加用普罗布考片治疗;两组患者均连续治疗6个月。比较两组患者治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、颈动脉内中膜厚度(IMT)及斑块面积、血脂指标〔总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)〕、血清氧化低密度脂蛋白(ox-LDL)和基质金属蛋白酶9(MMP-9)水平、不良反应发生情况。结果治疗前两组患者NIHSS评分比较,差异无统计学意义(P0.05);治疗后观察组患者NIHSS评分低于对照组(P0.05)。治疗前两组患者颈动脉IMT、斑块面积比较,差异无统计学意义(P0.05);治疗后观察组患者颈动脉IMT、斑块面积小于对照组(P0.05)。治疗前两组患者血清TC、TG、LDL-C、HDL-C水平比较,差异无统计学意义(P0.05);治疗后观察组患者血清TC、TG、LDL-C水平低于对照组(P0.05),而两组患者血清HDL-C水平比较,差异无统计学意义(P0.05)。治疗前两组患者血清ox-LDL、MMP-9水平比较,差异无统计学意义(P0.05);治疗后观察组患者血清ox-LDL、MMP-9水平低于对照组(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论普罗布考片联合阿托伐他汀钙片治疗大动脉粥样硬化型脑梗死的临床疗效优于单用阿托伐他汀钙片,可更有效地改善患者神经功能,缩小动脉粥样硬化斑块,调节血脂代谢及降低血清ox-LDL、MMP-9水平,且安全性较高。
[Abstract]:Objective to compare the clinical effects of probucol tablets combined with Atto vastatin calcium tablets and Atto vastatin calcium tablets in the treatment of atherosclerotic cerebral infarction. Methods from January 2012 to May 2015 110 patients with atherosclerotic cerebral infarction were randomly divided into control group and observation group with 55 cases in each group. On the basis of routine treatment, the patients in the control group were treated with Atto vastatin calcium tablets, while the patients in the observation group were treated with probucol tablets on the basis of the control group, and the patients in both groups were treated continuously for 6 months. The (NIHSS) score, carotid intima-media thickness (IMT) and plaque area were compared between the two groups before and after treatment. Serum lipids (total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) high density lipoprotein cholesterol (HDL-C),) serum oxidized low density lipoprotein (ox-LDL) and matrix metalloproteinase 9 (MMP-9) were measured. Results there was no significant difference in NIHSS score between the two groups before treatment (P0.05), while the NIHSS score in the observation group was lower than that in the control group (P0.05). Before treatment, there was no significant difference in carotid IMT, plaque area between the two groups (P0.05); after treatment, the carotid IMT area in the observation group was smaller than that in the control group (P0.05). Before treatment, there was no significant difference between the two groups in the level of serum TCU TGG LDL-C (P0.05); after treatment, the level of TCU TGG LDL-C in the observation group was lower than that in the control group (P0.05), but there was no significant difference in the serum HDL-C level between the two groups (P0.05). Before treatment, there was no significant difference in the levels of serum ox-LDLMP-9 between the two groups (P0.05); after treatment, the level of serum ox-LDL- MMP-9 in the observation group was lower than that in the control group (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion Probucol tablets combined with Atto vastatin calcium tablets are more effective than Atto calcareous tablets in the treatment of atherosclerotic cerebral infarction, which can effectively improve the neurological function and reduce atherosclerotic plaques. It was safe to regulate the metabolism of blood lipid and to decrease the level of MMP-9 in serum ox-LDL.
【作者单位】： 山东省威海市文登中心医院康复医学科;山东省威海市文登中心医院神经内科;山东省威海市文登中心医院护理部;
【分类号】：R743.33
本文编号：2161240
[Abstract]:Objective to compare the clinical effects of probucol tablets combined with Atto vastatin calcium tablets and Atto vastatin calcium tablets in the treatment of atherosclerotic cerebral infarction. Methods from January 2012 to May 2015 110 patients with atherosclerotic cerebral infarction were randomly divided into control group and observation group with 55 cases in each group. On the basis of routine treatment, the patients in the control group were treated with Atto vastatin calcium tablets, while the patients in the observation group were treated with probucol tablets on the basis of the control group, and the patients in both groups were treated continuously for 6 months. The (NIHSS) score, carotid intima-media thickness (IMT) and plaque area were compared between the two groups before and after treatment. Serum lipids (total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) high density lipoprotein cholesterol (HDL-C),) serum oxidized low density lipoprotein (ox-LDL) and matrix metalloproteinase 9 (MMP-9) were measured. Results there was no significant difference in NIHSS score between the two groups before treatment (P0.05), while the NIHSS score in the observation group was lower than that in the control group (P0.05). Before treatment, there was no significant difference in carotid IMT, plaque area between the two groups (P0.05); after treatment, the carotid IMT area in the observation group was smaller than that in the control group (P0.05). Before treatment, there was no significant difference between the two groups in the level of serum TCU TGG LDL-C (P0.05); after treatment, the level of TCU TGG LDL-C in the observation group was lower than that in the control group (P0.05), but there was no significant difference in the serum HDL-C level between the two groups (P0.05). Before treatment, there was no significant difference in the levels of serum ox-LDLMP-9 between the two groups (P0.05); after treatment, the level of serum ox-LDL- MMP-9 in the observation group was lower than that in the control group (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion Probucol tablets combined with Atto vastatin calcium tablets are more effective than Atto calcareous tablets in the treatment of atherosclerotic cerebral infarction, which can effectively improve the neurological function and reduce atherosclerotic plaques. It was safe to regulate the metabolism of blood lipid and to decrease the level of MMP-9 in serum ox-LDL.
【作者单位】： 山东省威海市文登中心医院康复医学科;山东省威海市文登中心医院神经内科;山东省威海市文登中心医院护理部;
【分类号】：R743.33
【相似文献】
相关期刊论文 前7条
1 向瑾;徐楠;余勤;王颖;梁茂植;苗佳;南峰;沈奇;秦永平;;普罗布考片单次口服给药的人体药物代谢动力学研究[J];华西医学;2012年07期
2 张德祥,朱兆仪,许树旭,温建华;普罗布考片的临床疗效[J];中国新药杂志;1998年01期
3 刘香;;普罗布考片合并荷丹片治疗高脂血症临床观察[J];内蒙古中医药;2014年16期
4 冷静;赵磊;李慧;;普罗布考片联合复方地龙胶囊对颈动脉粥样硬化斑块的影响[J];中国社区医师(医学专业);2012年32期
5 孙成龙;梁浩;韩衍银;李珂;齐永秀;;HPLC法同时测定阿托伐他汀钙片与普罗布考片中2主分含量[J];中国药房;2011年41期
6 邵卫;黄蓓;张忠文;陈国华;潘宋斌;;博心通胶囊治疗颈动脉不稳定粥样斑块的疗效观察[J];湖北中医杂志;2012年10期
7 ;[J];;年期
，本文编号：2161240
本文链接：https://www.wllwen.com/yixuelunwen/shenjingyixue/2161240.html
最近更新
教材专著
